From the Las Vegas Sun –
In April, Brasich received the first dose of ARV-110, making him the first patient in the world to receive this treatment. Before that happened and as with any clinical trial, there was a rigorous process for Brasich to qualify — including a deep dive into his medical records, scans, PSA counts and blood tests. Given the nature of a Phase I trial, Brasich must be monitored carefully for any side effects or adverse reactions. During a typical appointment, he takes several blood tests, undergoes EKGs and consults with his physicians before a dose is administered. The drug itself comes in pill form and may be consumed in a matter of seconds. On certain visits, he stays in the clinic for an entire day for continuous monitoring with EKGs and blood collections.